Morphic Announces Participation in Upcoming Investor Conferences
Morphic Therapeutic, a biopharmaceutical company focused on oral integrin therapies for chronic diseases, will participate in several investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Morphic Therapeutic, a biopharmaceutical company focused on oral integrin therapies for chronic diseases, will participate in several investor conferences. CEO Praveen Tipirneni will join a fireside chat at the Wells Fargo Virtual Healthcare Conference on September 10 at 8:40 am ET. Additionally, the management team will hold virtual meetings during the Citi 15th Annual BioPharma Virtual Conference from September 8 to 11. A live webcast of the Wells Fargo session will be available on Morphic's website, along with an archived replay post-conference.
Details
News Market Reaction – MORF
The recorded move for MORF in the trading session of this news was -0.60%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced participation in the following investor conferences:
- Praveen Tipirneni, M.D., president and chief executive officer is scheduled to take part in a fireside chat at 8:40 am ET on Thursday, September 10 at the 2020 Wells Fargo Virtual Healthcare Conference
- The Morphic management team will host virtual meetings during the Citi 15th Annual BioPharma Virtual Conference taking place from September 8 to 11
A live webcast of the Wells Fargo session will be available on the Investors section of Morphic’s website at https://www.morphictx.com. An archived replay will be available on the company’s website following the conference.
About Morphic Therapeutic
Morphic Therapeutic is a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. In collaboration with AbbVie, Janssen, and Schrödinger, Morphic is advancing its pipeline and discovery activities using its proprietary MInT technology platform which leverages the Company’s unique understanding of integrin structure and biology. For more information, visit www.morphictx.com.
Contacts
Morphic Therapeutic
Chris Erdman
chris.erdman@morphictx.com
617.686.1718
Media Contact
Tom Donovan, Ten Bridge Communications
tom@tenbridgecommunications.com
857.559.3397
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.